Cargando…

First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression

Detecting and treating Alzheimer’s disease, before cognitive deficits occur, has become the health challenge of our time. The earliest known event in Alzheimer’s disease is rising amyloid-β. Previous studies have suggested that effects on synaptic transmission may precede plaque deposition. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, Damian M., Liu, Wenfei, Portelius, Erik, Bayram, Sevinç, Yasvoina, Marina, Ho, Sui-Hin, Smits, Hélène, Ali, Shabinah S., Steinberg, Rivka, Pegasiou, Chrysia-Maria, James, Owain T., Matarin, Mar, Richardson, Jill C., Zetterberg, Henrik, Blennow, Kaj, Hardy, John A., Salih, Dervis A., Edwards, Frances A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572488/ https://www.ncbi.nlm.nih.gov/pubmed/25981962 http://dx.doi.org/10.1093/brain/awv127

Ejemplares similares

Effects of rising amyloidβ levels on hippocampal synaptic transmission, microglial response and cognition in APP(Swe)/PSEN1(M146V) transgenic mice
por: Medawar, Evelyn, et al.
Publicado: (2018)

Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk
por: Salih, Dervis A, et al.
Publicado: (2019)

A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease
por: Portelius, Erik, et al.
Publicado: (2010)

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
por: Sjödin, Simon, et al.
Publicado: (2015)

Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions
por: Liu, Wenfei, et al.
Publicado: (2020)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers
por: Rostgaard, Nina, et al.
Publicado: (2018)

Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus
por: Minta, Karolina, et al.
Publicado: (2021)

Update on fluid biomarkers for concussion
por: Zetterberg, Henrik, et al.
Publicado: (2016)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease
por: Jensen, Camilla Steen, et al.
Publicado: (2017)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
por: Kvartsberg, Hlin, et al.
Publicado: (2018)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer’s Disease
por: Brownjohn, Philip W., et al.
Publicado: (2017)

Wild-Type, but Not Mutant N296H, Human Tau Restores Aβ-Mediated Inhibition of LTP in Tau(−/−) mice
por: Vargas-Caballero, Mariana, et al.
Publicado: (2017)

Prediction of Outcome After Endovascular Embolectomy in Anterior Circulation Stroke Using Biomarkers
por: Pujol-Calderón, Fani, et al.
Publicado: (2021)

Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics
por: Behzadi, Arvin, et al.
Publicado: (2021)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons
por: Moore, Steven, et al.
Publicado: (2015)

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage
por: Portelius, Erik, et al.
Publicado: (2014)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
por: Hellwig, Konstantin, et al.
Publicado: (2015)

Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury
por: Minta, Karolina, et al.
Publicado: (2020)

Ex vivo(18)O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway
por: Portelius, Erik, et al.
Publicado: (2017)

Alzheimer-associated cerebrospinal fluid fragments of neurogranin are generated by Calpain-1 and prolyl endopeptidase
por: Becker, Bruno, et al.
Publicado: (2018)

Emergence of synaptic and cognitive impairment in a mature-onset APP mouse model of Alzheimer’s disease
por: Sri, Sarmi, et al.
Publicado: (2019)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans
por: Hölttä, Mikko, et al.
Publicado: (2016)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j9e6429g5sf3nk8krdp30v3vcl